SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Individuals interested in listening to the conference call may do so by dialing 1-800-289-0438 for domestic callers or 1-323-794-2423 for international callers. Please reference Conference ID: 2768596. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005194/en/
CareDx, Inc.
Investor Relations
Ian Cooney
415-287-2300 x 3550
investor@caredx.com
Source: CareDx, Inc.
